Palvella Therapeutics (PVLA) Receives a Buy from BTIG
I'm PortAI, I can summarize articles.
BTIG analyst Jeet Mukherjee has maintained a Buy rating on Palvella Therapeutics (PVLA) with a price target of $192.00 as of January 16. Mukherjee, a 4-star analyst with a 62.75% success rate, also covers other healthcare stocks. Additionally, Truist Financial's Danielle Brill issued a Buy rating for Palvella on the same day, while TipRanks reiterated a Hold rating on January 12.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments